Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse
Top Cited Papers
- 6 July 2003
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 9 (8), 1009-1014
- https://doi.org/10.1038/nm897
Abstract
As a target for gene therapy, Duchenne muscular dystrophy (DMD) presents many obstacles but also an unparalleled prospect for correction by alternative splicing. The majority of mutations in the dystrophin gene occur in the region encoding the spectrin-like central rod domain, which is largely dispensable. Thus, splicing around mutations can generate a shortened but in-frame transcript, permitting translation of a partially functional dystrophin protein. We have tested this idea in vivo in the mdx dystrophic mouse (carrying a mutation in exon 23 of the dystrophin gene) by combining a potent transfection protocol with a 2-O-methylated phosphorothioated antisense oligoribonucleotide (2OMeAO) designed to promote skipping of the mutated exon*. The treated mice show persistent production of dystrophin at normal levels in large numbers of muscle fibers and show functional improvement of the treated muscle. Repeated administration enhances dystrophin expression without eliciting immune responses. Our data establishes the realistic practicality of an approach that is applicable, in principle, to a majority of cases of severe dystrophinopathy. *NOTE: In the version of this article initially published online, the following errors appeared: The fourth sentence of the abstract was incorrect. It has been changed to, "We have tested this idea in vivo in the mdx dystrophic mouse (carrying a mutation in exon 23 of the dystrophin gene) by combining…to promote skipping of the mutated exon." The sixth sentence of the first paragraph of the Results was incorrect and has been changed. It now reads, "…(C57Bl/10ScSn; designated C57)…" Figure 2 and its legend contained an error. The figure should be labeled with subpanels a and b. The legend should read, "Figure 2 Detection of dystrophin and dystrophin protein complexes. Exon mapping of 2OMeAO-induced dystrophin (a,b) and detection of dystrophin protein complexes (b) in serial sections..." These mistakes have been corrected for the HTML and print versions of the article.Keywords
This publication has 25 references indexed in Scilit:
- Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene productGene Therapy, 2002
- Screening for antisense modulation of dystrophin pre-mRNA splicingNeuromuscular Disorders, 2002
- Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophyNeuromuscular Disorders, 2002
- Transfer of Full-Length Dmd to the Diaphragm Muscle of Dmdmdx/mdx Mice through Systemic Administration of Plasmid DNAMolecular Therapy, 2001
- Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouseProceedings of the National Academy of Sciences, 2000
- Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse modelProceedings of the National Academy of Sciences, 2000
- Dynamics of Myoblast Transplantation Reveal a Discrete Minority of Precursors with Stem Cell–like Properties as the Myogenic SourceThe Journal of cell biology, 1999
- Molecular genetics and genetic counselling for Duchenne/Becker muscular dystrophyPublished by Springer Nature ,1993
- An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locusGenomics, 1988
- Dystrophin: The protein product of the duchenne muscular dystrophy locusCell, 1987